" class="no-js "lang="en-US"> Freenome - Medtech Alert
Friday, December 01, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Freenome | Pharmtech Focus

Freenome

About Freenome

Freenome

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer.

We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science.

Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.

Related Story

Diseases

 Freenome Launches Its First Study for the Detection of Multiple Cancers That Pairs Multiomics With Real-World Data | Pharmtech Focus

Freenome Launches Its First Study for the Detection of Multiple Cancers That Pairs Multiomics With Real-World Data

September 8 2022

Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the […]

Clinical Trials

 Largest Clinical Study Validating A Blood-based Colorectal Screening Test Completes Enrollment | Pharmtech Focus

Largest Clinical Study Validating A Blood-based Colorectal Screening Test Completes Enrollment

May 11 2022

Freenome, a privately held biotech company, announced the completion of enrollment for PREEMPT CRC, the […]

Appointments

 Lance Baldo Joins Freenome as Chief Medical Officer | Pharmtech Focus

Lance Baldo Joins Freenome as Chief Medical Officer

April 5 2022

Freenome, a privately held biotech company, announced today that Lance Baldo, M.D. has joined the […]

Companies

 Freenome Launches The Vallania Study For The Early Detection Of Multiple Cancers | Pharmtech Focus

Freenome Launches The Vallania Study For The Early Detection Of Multiple Cancers

March 1 2022

Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study […]

Diseases

 Freenome Presents Research Highlighting its Multiomics Blood Testing Platform in PREEMPT CRC | Pharmtech Focus

Freenome Presents Research Highlighting its Multiomics Blood Testing Platform in PREEMPT CRC

January 24 2022

Freenome, a privately held biotech company, presented at the American Society of Clinical Oncology Gastrointestinal […]

Fundraising

 Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer | Pharmtech Focus

Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer

January 12 2022

Freenome, a privately held biotech company, announced today that Roche has made an investment of $290 […]

Fundraising

 Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection | Pharmtech Focus

Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection

December 8 2021

Freenome, a privately held biotech company, today announced a Series D funding of $300 million. […]

Diseases

 Freenome Shows Continued Leadership in Colorectal Cancer Research | Pharmtech Focus

Freenome Shows Continued Leadership in Colorectal Cancer Research

October 26 2021

Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology […]

Diseases

 New Study Finds Freenome ’s Multiomics Approach Successful in Detecting Pancreatic Cancer | Pharmtech Focus

New Study Finds Freenome ’s Multiomics Approach Successful in Detecting Pancreatic Cancer

October 1 2021

Freenome, a privately-held biotech company, presented new research today at the American Association of Cancer […]